Structure−Activity Relationships of the Cycloalkanol Ethylamine Scaffold: Discovery of Selective Norepinephrine Reuptake Inhibitors
作者:Paige E. Mahaney、Lori K. Gavrin、Eugene J. Trybulski、Gary P. Stack、An T. Vu、Stephen T. Cohn、Fei Ye、Justin K. Belardi、Arthur A. Santilli、Joseph P. Sabatucci、Jennifer Leiter、Grace H. Johnston、Jenifer A. Bray、Kevin D. Burroughs、Scott A. Cosmi、Liza Leventhal、Elizabeth J. Koury、Yingru Zhang、Cheryl A. Mugford、Douglas M. Ho、Sharon J. Rosenzweig-Lipson、Brian Platt、Valerie A. Smith、Darlene C. Deecher
DOI:10.1021/jm8002262
日期:2008.7
develop novel and selective norepinephrine reuptake inhibitors (NRIs) for evaluation in a variety of predictive animal models. These efforts led to the discovery of a piperazine-containing analogue, 17g (WY-46824), that exhibited potent norepinephrine reuptake inhibition, excellent selectivity over the serotonin transporter, but no selectivity over the dopamine transporter. Synthesis and testing of a series
进行了文拉法辛(1)参与的环烷醇乙胺支架的进一步探索,以开发新型和选择性的去甲肾上腺素再摄取抑制剂(NRI),以在各种预测性动物模型中进行评估。这些努力导致发现了含有哌嗪的类似物17g(WY-46824),该类似物表现出有效的去甲肾上腺素再摄取抑制作用,对5-羟色胺转运蛋白具有优异的选择性,但对多巴胺转运蛋白则没有选择性。合成和测试了一系列环己醇乙基哌嗪(S)-(-)-17i(WAY-256805),这是一种有效的去甲肾上腺素再摄取抑制剂(IC 50 = 82 nM,K i = 50 nM),在两种条件下均表现出优异的选择性。血清素和多巴胺转运蛋白,在抑郁,疼痛和体温调节功能障碍的动物模型中有效。